Target intelligence / Profile preview

HIV-1 capsid protein (CA) hexamer interface FG pocket (HIV-1 CA FG pocket)

Target
HIV-1 CA FG pocket
Molecular classification
Viral structural protein, Capsid protein, Protein-protein interface
01

Overview

The HIV-1 capsid protein (CA) hexamer interface FG pocket is a highly conserved hydrophobic site located at the junction of the N-terminal domain of one CA subunit and the C-terminal domain of an adjacent subunit within the hexameric lattice (PubMed: 32612211). This pocket is a critical functional hotspot that mediates the interaction between the viral capsid and essential host cell factors, including the nuclear pore protein NUP153 and the cleavage and polyadenylation specificity factor 6 (CPSF6) (PubMed: 24336210). These interactions are vital for the nuclear import of the viral pre-integration complex and the subsequent integration of viral DNA into the host genome. Therapeutic agents such as Lenacapavir (Sunlenca) target this pocket with picomolar affinity, effectively locking the capsid and disrupting multiple stages of the viral lifecycle, including assembly, uncoating, and nuclear transport (Nature, 2020, 583:114-118). Because the FG pocket is essential for viral fitness and is highly conserved across different HIV-1 strains, it represents a high-value target for long-acting antiretroviral therapies (NEJM, 2022, 386:1793-1803). The development of inhibitors for this site has provided a new treatment modality for patients with multi-drug resistant HIV-1 infection.

Other names
FG binding pocketCA-CA interface pocketPhenylalanine-glycine binding siteHIV-1 CA hexameric interfaceCapsid FG-binding site
02

Mechanism of action

Capsid inhibition via competitive binding at the FG pocket, which prevents interaction with host factors such as NUP153 and CPSF6, thereby disrupting capsid stability, uncoating, and nuclear transport (Nature, 2020, 583:114-118; PubMed: 32612211).

03

Biological functions

Viral capsid assemblyViral uncoatingNuclear importViral genome integrationReverse transcription regulation
04

Disease associations

HIV-1 infectionAcquired Immunodeficiency Syndrome (AIDS)
05

Safety considerations

Development of high-level resistance mutations (e.g., Q67H, K70N, N74D)Injection site reactions for long-acting formulationsLong pharmacokinetic tail requiring strict adherence to prevent resistancePotential for cross-resistance within the capsid inhibitor class
06

Interacting drugs

Lenacapavir

2 more in the full profile.

07

Biomarkers

Plasma HIV-1 RNA levels (viral load)CD4+ T-lymphocyte countHIV-1 CA gene resistance mutations (e.g., Q67H, N74D)

Beyond the preview

Go deeper on HIV-1 capsid protein (CA) hexamer interface FG pocket (HIV-1 CA FG pocket).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on HIV-1 capsid protein (CA) hexamer interface FG pocket (HIV-1 CA FG pocket).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call